Outset Medical, Inc. OM
We take great care to ensure that the data presented and summarized in this overview for Outset Medical, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OM
View all-
Ameriprise Financial Inc Minneapolis, MN5.11MShares$22.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.01MShares$17.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.27MShares$14.2 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.11MShares$13.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.89MShares$12.6 Million0.0% of portfolio
-
Braidwell LP Stamford, CT2.4MShares$10.4 Million0.17% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY1.69MShares$7.33 Million0.0% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT1.6MShares$6.98 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.22MShares$5.32 Million0.0% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA1.17MShares$5.08 Million0.13% of portfolio
Latest Institutional Activity in OM
Top Purchases
Top Sells
About OM
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Insider Transactions at OM
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 12
2024
|
John L. Brottem General Counsel |
SELL
Open market or private sale
|
Direct |
10,569
-4.33%
|
$42,276
$4.78 P/Share
|
Jun 03
2024
|
D Keith Grossman Director |
SELL
Open market or private sale
|
Direct |
38,117
-24.63%
|
$114,351
$3.77 P/Share
|
Jun 03
2024
|
D Keith Grossman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
69,303
+30.18%
|
$69,303
$1.11 P/Share
|
May 29
2024
|
Dale E Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+35.25%
|
-
|
May 29
2024
|
Brent D. Lang Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+15.82%
|
-
|
May 29
2024
|
Andrea Lynn Saia Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+34.3%
|
-
|
May 29
2024
|
Patrick T Hackett Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+36.85%
|
-
|
May 29
2024
|
James F. Hinrichs Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+23.73%
|
-
|
May 29
2024
|
Karen Drexler Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+34.14%
|
-
|
May 29
2024
|
D Keith Grossman Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+36.85%
|
-
|
May 16
2024
|
Nabeel Ahmed Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,918
-1.21%
|
$11,754
$3.53 P/Share
|
May 16
2024
|
John L. Brottem General Counsel |
SELL
Open market or private sale
|
Direct |
2,972
-1.2%
|
$8,916
$3.53 P/Share
|
May 16
2024
|
Marc Nash SVP Operations and R&D |
SELL
Open market or private sale
|
Direct |
1,097
-0.45%
|
$3,291
$3.53 P/Share
|
May 16
2024
|
Leslie Trigg Chair and CEO |
SELL
Open market or private sale
|
Direct |
5,237
-0.57%
|
$15,711
$3.53 P/Share
|
May 10
2024
|
Jean Olivier Racine Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
8,306
-3.04%
|
$24,918
$3.27 P/Share
|
Mar 15
2024
|
Marc Nash SVP Operations and R&D |
SELL
Open market or private sale
|
Direct |
2,391
-0.98%
|
$4,782
$2.13 P/Share
|
Mar 12
2024
|
Brent D. Lang Director |
BUY
Grant, award, or other acquisition
|
Direct |
108,024
+50.0%
|
-
|
Mar 01
2024
|
Nabeel Ahmed Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,584
-0.49%
|
$4,752
$3.15 P/Share
|
Feb 29
2024
|
Nabeel Ahmed Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
1,584
+0.49%
|
$3,168
$2.68 P/Share
|
Feb 23
2024
|
Nabeel Ahmed Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,639
-3.19%
|
$31,917
$3.72 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.96M shares |
---|---|
Other acquisition or disposition | 1.58K shares |
Exercise of conversion of derivative security | 111K shares |
Payment of exercise price or tax liability | 56.2K shares |
---|---|
Open market or private sale | 219K shares |